Author:
Shustik C.,Bence-Bruckler I.,Delage R.,Owen C. J.,Toze C. L.,Coutre S.
Publisher
Springer Science and Business Media LLC
Subject
Hematology,General Medicine
Reference79 articles.
1. Hallek M, Fischer K, Fingerle-Rowson G et al (2010) Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 376:1164–1174
2. Robak T, Dmoszynska A, Solal-Céligny P et al (2010) Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol 28:1756–1765
3. Howlader N, Noone AM, Krapcho M, et al. (eds). SEER Cancer Statistics Review, 1975–2013, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2013/ , based on November 2015 SEER data submission, posted to the SEER web site, April 2016.
4. Statistics Canada. Table 1030553: new cases and 1991 agestandardized rate for primary cancer (based on the August 2015 CCR tabulation file), by cancer type and sex, Canada, provinces and territories. Available at: http://www5.statcan.gc.ca/cansim/a26?lang=eng&id=1030553 . Accessed November 16, 2016.
5. Eichhorst B, Dreyling M, Robak T, Montserrat E, Hallek M, ESMO Guidelines Working Group (2011) Chronic lymphocytic leukemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 22(Suppl 6):vi50–vi54
Cited by
21 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献